Phase I LPCN 1144 Clinical Study
Lipocine (LPCN) reported the 8-week top line interim result from Liver Fat Study using magnetic resonance imaging, proton density fat fraction (“MRI-PDFF”) technique on January 17, 2019. LPCN 1144 is an oral prodrug that contains bioidentical testosterone and the company is conducting two POC clinical studies for the NASH/NAFLD indication. The stock went up over 100% after the first hours of trading and finished the day up 18%. Following the excellent 8-week interim results, the company is well positioned to report top line 16-week interim results later